Pieter Droppert

Pieter Droppert is a management consultant, lawyer, science writer and editor of the Biotech Strategy Blog (http://biotechstrategyblog.com) on science, innovation and new product development in the pharma & biotech industries.

Recent posts

A Revolution is Taking Place in the Treatment of Blood Cancers
I try to avoid sensationalizing early clinical trial results presented at medical conferences, what’s commonly known as “hype over hope.” But at this year’s annual meeting of the American Society of... Read more »
Is Crowdfunding The Future For Biomedical Research?
Microryza.com (not the catchiest of names) is a crowdfunding platform for research that raises money over the Internet from individuals who are willing to donate small amounts to fund a specific... Read more »
Prostate Cancer Drug Winners and Losers at ASCO GU
The latest clinical research in prostate cancer is being presented at the American Society of Clinical Oncology Genitorinary Cancers Symposium (ASCO GU) in Orlando, FL. Presentations started yesterday, and run through... Read more »
Emerging Challenges of Prostate Cancer Drug Development
The world’s largest cancer meeting of scientists, physicians and industry has just ended in Chicago. The annual meeting of the American Society of Clinical Oncology (ASCO) attracted over 30,000 attendees to... Read more »
J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early
One of the more anticipated clinical trials at this year’s American Society of Clinical Oncology (ASCO) meeting was for Johnson & Johnson’s abiraterone (Zytiga) in prostate cancer patients. This study, known... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex

Xconomy on Demand

We offer a number of ways to subscribe for free!

Subscribe Now

Xconomy National

Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4

FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats

Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

BIO Launches 'Biotech Votes' Campaign to Encourage Registration and Informed Voting

Pieter Droppert

Recent posts

A Revolution is Taking Place in the Treatment of Blood Cancers

Is Crowdfunding The Future For Biomedical Research?

Prostate Cancer Drug Winners and Losers at ASCO GU

Emerging Challenges of Prostate Cancer Drug Development

J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early

Underwriters and Partners

Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes

The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace

What to Include in Your Life Sciences Company Fundraising Pitch Deck

Xconomy on Demand

We offer a number of ways to subscribe for free!